Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN N.V. (QGEN) has successfully priced new senior, unsecured convertible bonds totaling $500 million, due in 2027. The bonds, with an initial conversion price set at $80.7218 per share, will be issued at 100% of their principal amount and pay no interest. Concurrently, the company is repurchasing $172.8 million of outstanding convertible notes due in 2021. The proceeds from the new bonds will be used for the repurchase and general corporate purposes. Settlement for both transactions is expected on December 17, 2020.
QIAGEN (NYSE: QGEN) has raised its full-year 2020 forecast for net sales and adjusted earnings per share, anticipating strong performance in 2021 driven by its focus on five growth pillars. The company also plans to expand its Supervisory Board to enhance expertise in Life Sciences and diagnostics. CEO Thierry Bernard acknowledged the team's efforts during the COVID-19 pandemic, highlighting the launch of new testing solutions and increased production capacity. QIAGEN will host a Virtual Deep Dive on December 8 for a strategic and financial update.
QIAGEN N.V. has launched the QuantiFERON SARS-CoV-2 RUO solution, designed to detect T-cell responses to COVID-19. This innovative technology enables researchers to assess immunity levels and disease progression more effectively, as studies show T-cell responses decline slower than antibody responses. With the ability to indicate disease severity and long-term immunity, this tool enhances QIAGEN's COVID-19 portfolio, which includes sample-preparation technology and PCR testing.
QIAGEN N.V. has entered a strategic collaboration with BioNTech SE to develop a tissue-based companion diagnostic for identifying patients with head and neck squamous cell carcinoma (SCCHN) linked to human papilloma virus (HPV) infections. Utilizing QIAGEN’s RGQ MDx platform, the assay aims to expand its applications across various HPV-related cancers. With over 650,000 new SCCHN cases annually, and projections indicating doubled numbers by 2035, this collaboration positions QIAGEN to enhance its HPV diagnostic offerings, building on its established market leadership.
QIAGEN N.V. (NYSE: QGEN) has launched the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test in Europe, addressing the need for rapid diagnosis during flu season. This multiplex PCR test can differentiate between influenza A and B, RSV, and SARS-CoV-2 in just 80 minutes, aiding healthcare professionals in treatment decisions amidst similar respiratory symptoms. Following CE-IVD registration, the test has also received a request for Emergency Use Authorization from the FDA. The company has additionally expanded the use of saliva samples in its existing SARS-CoV-2 test.
QIAGEN has launched the QIAreach™ SARS-CoV-2 Antigen Test in the U.S., enabling rapid detection of SARS-CoV-2 antigens in 2-15 minutes for active infections. Developed with Ellume, the test can process over 30 samples per hour and offers digital results without subjective interpretation. An EUA application for symptomatic patients has been submitted, with plans for a POC claim later this year. The test addresses the need for scalable and accurate antigen testing as part of COVID-19 strategies, complementing PCR testing for higher throughput.
QIAGEN N.V. (NYSE: QGEN) announced a conference call set for October 28 to discuss third-quarter results for 2020, following the release of their financial report on October 27. The call will be at 14:00 Frankfurt time/13:00 London time/9:00 New York time, hosted by CEO Thierry Bernard and CFO Roland Sackers. Interested participants can join via phone or by accessing the webcast. QIAGEN specializes in Sample to Insight solutions, serving over 500,000 customers globally in Molecular Diagnostics and Life Sciences as of September 30, 2020.
QIAGEN N.V. (NYSE: QGEN) reported robust Q3 2020 results, with sales escalating by 26% to $483.8 million compared to $382.7 million in Q3 2019. Adjusted EPS soared 61% to $0.58. Encouraged by this performance, the company raised its 2020 outlook, forecasting 20% sales growth and adjusted EPS of $2.07-2.09. The significant sales increase is attributed to high demand for COVID-19 related products, alongside other portfolio areas. QIAGEN also expanded its COVID-19 testing capabilities and solidified its position in automated molecular testing through a recent acquisition.
QIAGEN N.V. (NYSE: QGEN) reported strong preliminary results for Q3 2020, with net sales rising 26% year-over-year to $481.3 million, surpassing prior growth forecasts. This growth is attributed to heightened demand for COVID-19 testing solutions, along with improved trends in non-COVID product sales. Adjusted EPS reached approximately $0.58, marking a 61% increase from $0.36 in Q3 2019. QIAGEN anticipates minimal currency impact on its results. Full Q3 results will be published on November 4, 2020, with a conference call scheduled for November 5.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
